ABSTRACT
ABSTRACT Minimally invasive glaucoma surgeries are surgical treatment alternatives for glaucoma aimed at reducing intraocular pressure with a better safety profile compared to traditional trabeculectomy. However, in spite of less invasive techniques, complications may develop in any surgical procedure. To the best of our knowledge, this is the first case report of anterior uveitis following combined treatment with cataract surgery and iStent inject® which addresses the management of postoperative inflammation.
RESUMO As cirurgias minimamente invasivas para glaucoma consistem em uma opção de tratamento cirúrgico para glaucoma, a qual promove redução da pressão intraocular com melhor perfil de segurança do que a trabeculectomia. Todavia, complicações são inerentes à realização de procedimentos cirúrgicos, apesar do uso de técnicas menos invasivas. Este é o primeiro relato que apresenta um caso de uveíte anterior após cirurgia combinada de catarata e iStent inject®, além de orientações quanto ao manejo do quadro inflamatório.
Subject(s)
Humans , Female , Middle Aged , Uveitis/drug therapy , Cataract Extraction/adverse effects , Uveitis, Anterior/etiology , Postoperative Complications , Titanium , Trabecular Meshwork/surgery , Tropicamide/administration & dosage , Dexamethasone/administration & dosage , Stents , Glaucoma, Open-Angle/surgery , Injections, Intraocular , Intraocular Pressure , Acetazolamide/administration & dosageABSTRACT
BACKGROUND: The purpose of this study was to determine any difference in dynamic contour tonometry and ocular pulse amplitude in asymmetric glaucoma patients with the same applanation intraocular pressure. METHODS: This is a prospective, observational study of 30 glaucoma patients and 11 controls from June 2007 to February 2008. Most of the glaucoma patients were on prostaglandin analog treatment. RESULTS: Mean applanation intraocular pressure in the control group was 14.28 mmHg for the right eye and 14.10 mmHg for the left eye (P > 0.05). Corneal thickness was 519.10 µm for the right eye and 511.07 µm for the left eye (P > 0.05). Mean dynamic contour tonometry intraocular pressure was 17.28 mmHg for the right eye and 17.25 mmHg for the left eye (P > 0.05). Mean ocular pulse amplitude was 2.80 mmHg for the right eye and 2.92 mmHg for the left eye (P > 0.05). CONCLUSION: No differences in ocular pulse amplitude were found between the two groups and between the worst and the best eye. In spite of there being no difference in ocular pulse amplitude, dynamic contour tonometry intraocular pressure was 2.44 mmHg higher in the worst eye than in the best eye in the glaucoma patients, even with the same applanation intraocular pressure. Further studies are needed to confirm if this difference is related to glaucoma progression or a worst prognosis and whether it can be considered to be a new risk factor.
ABSTRACT
Travoprost is a prostaglandin analog used in the management of glaucoma and ocular hypertension for reducing intraocular pressure (IOP). The IOP-lowering efficacy of travoprost has been shown to be similar to that of other prostaglandins, including latanoprost and bimatoprost. When compared with fixed combinations of timolol and either latanoprost or dorzolamide, travoprost alone can reduce mean IOP in a similar or superior manner. Concomitant therapy of travoprost and timolol can reach even greater IOP reductions than fixed combinations at some time points, but with no difference in the early morning, when IOP is usually higher. In addition, the long duration of action of travoprost can also provide better control of IOP fluctuation, probably due to its stronger prostaglandin F receptor mechanism. The side effects of travoprost do not represent a risk to the vision or health of the patient. The proven efficacy and safety combined with convenient once-daily dosing for travoprost increases patient compliance with treatment for glaucoma.
